Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Add-on dapagliflozin improves outcomes in uncontrolled T2D

22 May 2021

Patients with type 2 diabetes (T2D) uncontrolled on current insulin therapy may benefit from adjunctive dapagliflozin, which has been shown to enhance glycaemic control and additionally lead to weight loss, reduction in insulin requirement, and fewer hypoglycaemic events.

Add-on dapagliflozin improves outcomes in uncontrolled T2D

22 May 2021

Ibrexafungerp shows promise as first non-azole treatment for vulvovaginal candidiasis

21 May 2021 bởi

The novel oral triterpenoid antifungal ibrexafungerp demonstrated superiority over placebo in reducing signs and symptoms of vulvovaginal candidiasis, according to results of the phase III VANISH-306 trial presented at ACOG 2021.

Ibrexafungerp shows promise as first non-azole treatment for vulvovaginal candidiasis

21 May 2021

Once-nightly narcolepsy drug formula may benefit sleepyheads

21 May 2021 bởi

Use of FT218, an investigational, once-nightly, controlled-release formulation of sodium oxybate (SO), led to clinically significant improvements in sleep parameters in individuals with narcolepsy, according to the secondary endpoint data from the pivotal phase III REST-ON* trial presented at AAN 2021.

Once-nightly narcolepsy drug formula may benefit sleepyheads

21 May 2021

Long-term DAPT should remain SoC post-PCI in high-risk ACS patients

20 May 2021 bởi

Dual antiplatelet therapy (DAPT) for >12 months should remain the standard of care (SoC) for high-risk patients with acute coronary syndrome (ACS) who have undergone percutaneous coronary intervention (PCI), suggested a study presented at SCAI 2021.

Long-term DAPT should remain SoC post-PCI in high-risk ACS patients

20 May 2021

$Lower oesophageal sphincter pressure, length peg baclofen efficacy in refractory GERC$

Lower oesophageal sphincter pressure, length peg baclofen efficacy in refractory GERC

20 May 2021

In the treatment of refractory gastroesophageal reflux-induced chronic cough (GERC), the lower oesophageal sphincter pressure (LESP) and lower oesophageal sphincter length (LESL) help predict baclofen efficacy, according to a study.

Lower oesophageal sphincter pressure, length peg baclofen efficacy in refractory GERC

20 May 2021

Ubrogepant continues to show benefit for migraine, subgroup analyses show

20 May 2021 bởi

Subgroup analyses of the ACHIEVE I and II studies presented at AAN 2021 continued to demonstrate favourable outcomes associated with the 50-mg dose of the FDA-approved oral CGRP* receptor antagonist ubrogepant for acute treatment of migraine in adults, particularly among those who were classified as “triptan-insufficient responders”**. Its safety and tolerability were also consistent across various demographic and clinical characteristic subgroups.

Ubrogepant continues to show benefit for migraine, subgroup analyses show

20 May 2021

$Decitabine plus camrelizumab shows activity against relapsed, refractory cHL$

Decitabine plus camrelizumab shows activity against relapsed, refractory cHL

20 May 2021

Treatment with the combination of decitabine plus camrelizumab yields high response rates and long-term benefits in patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who failed programmed death-1 (PD-1) inhibitors, as shown in a study.

Decitabine plus camrelizumab shows activity against relapsed, refractory cHL

20 May 2021

Lack of reproductive aged women in COVID-19 trials has long-ranging effects

19 May 2021 bởi

Women of reproductive age are often excluded from COVID-19 vaccine and treatment clinical trials, which could hinder their access to beneficial treatments, according to a study presented at the recent ACOG 2021 meeting.

Lack of reproductive aged women in COVID-19 trials has long-ranging effects

19 May 2021

Dapirolizumab pegol for systemic lupus shows efficacy signal

19 May 2021

Patients with systemic lupus erythematosus (SLE) appear to exhibit improvements with dapirolizumab pegol in a phase IIb trial, which, however, did not meet its primary endpoint.

Dapirolizumab pegol for systemic lupus shows efficacy signal

19 May 2021

Biosimilar ranibizumab measures up to original for nAMD

19 May 2021 bởi

In the treatment of patients with neovascular age-related macular degeneration (nAMD), the biosimilar FYB201 appears to have similar efficacy, safety, and immunogenicity as ranibizumab, as shown in the results of a phase III study.

Biosimilar ranibizumab measures up to original for nAMD

19 May 2021

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Add-on dapagliflozin improves outcomes in uncontrolled T2D

Add-on dapagliflozin improves outcomes in uncontrolled T2D

Ibrexafungerp shows promise as first non-azole treatment for vulvovaginal candidiasis

Ibrexafungerp shows promise as first non-azole treatment for vulvovaginal candidiasis

Once-nightly narcolepsy drug formula may benefit sleepyheads

Once-nightly narcolepsy drug formula may benefit sleepyheads

Long-term DAPT should remain SoC post-PCI in high-risk ACS patients

Long-term DAPT should remain SoC post-PCI in high-risk ACS patients

Lower oesophageal sphincter pressure, length peg baclofen efficacy in refractory GERC

Lower oesophageal sphincter pressure, length peg baclofen efficacy in refractory GERC

Ubrogepant continues to show benefit for migraine, subgroup analyses show

Ubrogepant continues to show benefit for migraine, subgroup analyses show

Decitabine plus camrelizumab shows activity against relapsed, refractory cHL

Decitabine plus camrelizumab shows activity against relapsed, refractory cHL

Lack of reproductive aged women in COVID-19 trials has long-ranging effects

Lack of reproductive aged women in COVID-19 trials has long-ranging effects

Dapirolizumab pegol for systemic lupus shows efficacy signal

Dapirolizumab pegol for systemic lupus shows efficacy signal

Biosimilar ranibizumab measures up to original for nAMD

Biosimilar ranibizumab measures up to original for nAMD